H-Gemcitabine: A new gemcitabine prodrug for treating cancer

  • Madhuri Dasari
  • , Abhinav P. Acharya
  • , Dongin Kim
  • , Seungjun Lee
  • , Sungmun Lee
  • , Jeanne Rhea
  • , Ross Molinaro
  • , Niren Murthy

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

Original languageBritish English
Pages (from-to)4-8
Number of pages5
JournalBioconjugate Chemistry
Volume24
Issue number1
DOIs
StatePublished - 16 Jan 2013

Fingerprint

Dive into the research topics of 'H-Gemcitabine: A new gemcitabine prodrug for treating cancer'. Together they form a unique fingerprint.

Cite this